Rhythm Pharmaceuticals (RYTM)
(Real Time Quote from BATS)
$43.58 USD
-0.45 (-1.02%)
Updated Aug 6, 2024 10:02 AM ET
4-Sell of 5 4
F Value D Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RYTM 43.58 -0.45(-1.02%)
Will RYTM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RYTM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RYTM
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Misses Revenue Estimates
RYTM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Amicus Therapeutics (FOLD) Report Negative Q1 Earnings? What You Should Know
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Expected to Decline
Moderna (MRNA) Surges 6.2%: Is This an Indication of Further Gains?
Other News for RYTM
Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update
Rhythm Pharmaceuticals Inc (RYTM) Q2 2024 Earnings: Revenue of $29. ...
Rhythm Pharmaceuticals GAAP EPS of -$0.55 beats by $0.15, revenue of $29.08M beats by $0.29M
Rhythm Pharmaceuticals reports Q2 EPS (55c), consensus (71c)
Rhythm Pharmaceuticals Q2 2024 Earnings Preview